Source comparison
Hexarelin vs Other GH Secretagogues: Peptide Comparison
Before committing to a Hexarelin protocol, researchers often compare it to alternative growth hormone secretagogues. Here's how Hexarelin stacks against the most common alternatives in controlled research settings. Hexarelin GHS-R1a agonist (ghrelin receptor)
This comparison does not assign a generated winner or score.
- Before committing to a Hexarelin protocol, researchers often compare it to alternative growth hormone secretagogues. Here's how Hexarelin stacks against the most common alternatives in controlled research settings.
- Hexarelin
- GHS-R1a agonist (ghrelin receptor)
- 7–15× baseline within 30 min
- Noticeable by week 3–4, significant by week 6
- Strong synergy with CJC-1295 (GH pulse amplitude + frequency)
- Highest acute GH pulse but fastest desensitisation. Best for short 4–6 week cycles with structured off periods
- GHRP-2
- GHS-R1a agonist (weaker binding affinity)
- 4–8× baseline within 30 min
- Slower desensitisation; maintains 70% response at 8 weeks
- Moderate synergy with CJC-1295
- Lower peak GH but more sustainable over 8–12 week cycles. Better for extended research timelines
- GHRP-6
- GHS-R1a agonist (similar to GHRP-2) + appetite stimulation
- 4–7× baseline within 30 min
- Minimal desensitisation up to 12 weeks
- Comparable to GHRP-2 but increases hunger significantly. Useful when caloric surplus is desired, counterproductive for fat loss
- Ipamorelin
- Selective GHS-R1a agonist (minimal ACTH/cortisol co-release)
- 2–5× baseline within 30 min
- Very slow desensitisation; 85% response maintained at 12 weeks
- Excellent synergy with CJC-1295 without cortisol spike
- Gentlest GH secretagogue with lowest side-effect profile. Ideal for sensitive populations or long research periods
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- 2–4× baseline sustained over 24 hours
- Significant desensitisation after 6–8 months
- No synergy (already 24-hour active; stacking redundant)
- Convenient oral dosing but slower onset, water retention common, and year-long daily use required. Not ideal for short fat-loss research
- CJC-1295 (DAC)
- GHRH analogue (increases GH pulse frequency)
- Does not spike GH acutely; extends natural pulse duration
- No direct desensitisation (works via different pathway)
- Essential for stacking with any GHS-R1a agonist
- Does not work alone for fat loss. Synergises with Hexarelin/GHRP to amplify total GH exposure per 24-hour period
- Hexarelin produces the highest single-dose GH spike of any peptide secretagogue, making it exceptionally effective for short-duration fat-loss research where maximum lipolytic signalling is the goal. However, its rapid receptor desensitisation means protocols extending beyond 6 weeks produce diminishing returns. For researchers planning 8–12 week timelines, GHRP-2 or Ipamorelin paired with CJC-1295 may yield more consistent results across the full duration.